NZ604127A - Neuroendocrine tumor treatment using mtor inhibitors - Google Patents

Neuroendocrine tumor treatment using mtor inhibitors

Info

Publication number
NZ604127A
NZ604127A NZ604127A NZ60412706A NZ604127A NZ 604127 A NZ604127 A NZ 604127A NZ 604127 A NZ604127 A NZ 604127A NZ 60412706 A NZ60412706 A NZ 60412706A NZ 604127 A NZ604127 A NZ 604127A
Authority
NZ
New Zealand
Prior art keywords
mtor inhibitors
tumor treatment
neuroendocrine tumor
tumours
rapamycin
Prior art date
Application number
NZ604127A
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to NZ622710A priority Critical patent/NZ622710A/en
Publication of NZ604127A publication Critical patent/NZ604127A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed is the use of 40-O-(2-hydroxyethyl)-rapamycin in the manufacture of a medicament for treating pancreatic endocrine tumours, wherein the tumours are advanced tumours after failure of cytotoxic chemotherapy as a monotherapy and wherein the medicament is formulated to provide a dose of 10 mg/day of 40-O-(2-hydroxyethyl)-rapamycin.
NZ604127A 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors NZ604127A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ622710A NZ622710A (en) 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14
NZ58716306 2006-11-20

Publications (1)

Publication Number Publication Date
NZ604127A true NZ604127A (en) 2014-05-30

Family

ID=58408253

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ604127A NZ604127A (en) 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors

Country Status (1)

Country Link
NZ (1) NZ604127A (en)

Similar Documents

Publication Publication Date Title
IN2012DN01964A (en)
NO20082683L (en) Neuroendocrine tumor therapy
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
MX2023008716A (en) Camptothecin compound, preparation method therefor, and application thereof.
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
TW200718689A (en) 2-Amino-quinazolin-5-ones
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
MX2008012422A (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors.
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
HK1120441A1 (en) Drugs for treatment of ovarian cancer
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2007004955A (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally.
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
MX2013010770A (en) Treatment of solid tumours.
WO2005117542A3 (en) Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
EP1971338B8 (en) Combination of zd6474 and pemetrexed
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
EP2061456A4 (en) Compositions and methods for inhibiting cytochrome p450
MX2008015775A (en) Compounds and compositions for treatment of cancer.
TW200631606A (en) Organic compounds
EA201071352A1 (en) TRICYCLIC NITROGEN-CONTAINING COMPOUNDS AND THEIR APPLICATION AS BACTERICIDAL MEANS
MY158929A (en) Pharmaceutical combination

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 20 NOV 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140909

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2017 BY CPA GLOBAL

Effective date: 20161021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2018 BY CPA GLOBAL

Effective date: 20171019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2019 BY CPA GLOBAL

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2020 BY CPA GLOBAL

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2021 BY CPA GLOBAL

Effective date: 20201022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2022 BY CPA GLOBAL

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2023 BY CPA GLOBAL

Effective date: 20221020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2024 BY CPA GLOBAL

Effective date: 20231019